We hope to serve our community with infusions to help this unmet medical need while continuing to work on the next generation of Alzheimer treatments.
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
In the narrow window in which patients are aware of their disease, they have sought help in clinical trials. But enrolling enough participants to make these trials count is not easy.
In patients with early Alzheimer’s disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.
Donanemab, an investigational antibody that targets a modified form of beta amyloid, showed significant slowing of decline in cognition and daily function.